TeaRx Overview
- Year Founded
-
2011
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
TeaRx General Information
Description
Developer of therapeutic drugs intended to prevent deep venous thrombosis (DVT) and pulmonary embolism (PE). The company's drug is a new class of anticoagulants-blood coagulation factor Xa inhibitors and has a thioredoxin molecule that is required during the treatment of a range of diseases, as well as for the most surgical procedures, enabling medical institutions to prevent thromboembolism in patients and save lives.
Contact Information
Website
www.tearx.ruCorporate Office
- Khimki 2a/1, Rabochaya Street
- Building 1
- Moscow, 141400
- Russia
Corporate Office
- Khimki 2a/1, Rabochaya Street
- Building 1
- Moscow, 141400
- Russia
TeaRx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 18-Aug-2026 | Completed | Out of Business | |||
| 1. Early Stage VC | Completed | Clinical Trials - Phase 2 |
TeaRx FAQs
-
When was TeaRx founded?
TeaRx was founded in 2011.
-
Where is TeaRx headquartered?
TeaRx is headquartered in Moscow, Russia.
-
What industry is TeaRx in?
TeaRx’s primary industry is Drug Discovery.
-
Is TeaRx a private or public company?
TeaRx is a Private company.
-
What is TeaRx’s current revenue?
The current revenue for TeaRx is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process